Truist reiterates Buy on Collegium Pharmaceutical stock

Collegium Pharmaceutical’s $650 million AZSTARYS acquisition is expected to be immediately EBITDA accretive, with more than $50 million in annual synergies and potential peak sales of about $400 million by 2036. The deal adds an established ADHD franchise with roughly 750,000 scripts and IP protection through 2037, while reinforcing the existing Jornay PM portfolio. Earnings were mixed, as Q4 2025 EPS of $2.04 and revenue of $205.45 million both came in slightly below estimates, but multiple analysts reiterated Buy/Overweight ratings with price targets of $51 and $56.

Analysis

The market is likely underestimating how much this deal changes the earnings quality mix rather than just the top-line profile. A high-margin, patent-protected ADHD asset layered onto an already cash-generative base should compress the path to deleveraging if integration stays clean, which matters more than the headline purchase price because the equity is currently being valued like a single-product story. The immediate read-through is that the stock can re-rate on multiple expansion before any meaningful contribution from the acquired asset shows up in reported numbers.

The second-order effect is competitive, not operational: the company now has enough scale in the category to defend salesforce economics better than smaller ADHD players, but that same scale raises the bar for execution. Any softness in script retention or payer pushback would be punished more because investors are now paying for a portfolio thesis, not a standalone franchise. That creates a sharper asymmetry over the next 1-2 quarters: good integration data could drive a fast rerating, while a single quarter of integration friction would compress the multiple quickly.

The consensus seems too comfortable assuming synergies and prescription conversion are largely mechanical. In reality, the key risk is not the acquisition itself but whether management can sustain growth while avoiding dilution in the core product as field teams prioritize the new launch. If the market starts to believe the combined opportunity is worth a higher terminal EBITDA multiple, the stock can work even without immediate earnings beats; if not, it remains a low-multiple value trap with a long-dated catalyst set.

The contrarian angle is that the setup may actually be better for a tactical trade than a long-term hold: the next few catalysts are discrete, while the full bear case depends on slow-moving integration decay. That favors expressing the view with options or a paired trade rather than an outright long if you want convexity around the next update cycle.

Key Decisions for Investors

• Go long COLL into the next quarterly print or integration update, targeting a 3-6 month window; upside comes from multiple expansion if management demonstrates seamless cross-sell and synergy capture, while downside is limited if the market is already anchored to a depressed EBITDA multiple.
• Buy COLL call spreads 3-6 months out to express a catalyst-driven rerating with defined risk; the setup favors convexity because the stock can gap on integration confidence before fundamentals fully inflect.
• Pair trade: long COLL / short a lower-quality ADHD or specialty pharma peer with weaker patent visibility and less salesforce leverage; the relative thesis is that scaled category ownership should command a premium once investors focus on durability rather than just acquisition cost.
• If already long, trim on any sharp post-catalyst move and re-add only on evidence of script stability; the main failure mode is not a headline miss but slower-than-expected conversion that shows up 1-2 quarters later.